However, the AChE activity remains unchanged or even decreases in AD, while BuChE progressively increases, suggesting that inhibition of both enzymes may be considered a valid approach for AD therapy, increasing levels of AChE [26]. This evidence concerns the gene ACHE and Alzheimer disease.